Related references
Note: Only part of the references are listed.Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway
Xiaozhen Liu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Irisin ameliorates high glucose-induced cardiomyocytes injury via AMPK/mTOR signal pathway
Jingyu Deng et al.
CELL BIOLOGY INTERNATIONAL (2020)
Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis
Karen McQuillan et al.
FRONTIERS IN PHARMACOLOGY (2020)
Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics
Hitesh B. Mistry et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis
Wei Lu et al.
DEVELOPMENTAL CELL (2019)
Roles of E-cadherin and Noncoding RNAs in the Epithelial-mesenchymal Transition and Progression in Gastric Cancer
Irina V. Bure et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Changes in store for early-stage non-small cell lung cancer
Jason E. Sandler et al.
JOURNAL OF THORACIC DISEASE (2019)
Anti-angiogenesis triggers exosomes release from endothelial cells to promote tumor vasculogenesis
Ye Zeng et al.
JOURNAL OF EXTRACELLULAR VESICLES (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner
Shanshan Sun et al.
CLINICAL CANCER RESEARCH (2018)
An overview of apoptosis assays detecting DNA fragmentation
Pavlina Majtnerova et al.
MOLECULAR BIOLOGY REPORTS (2018)
EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy
Hongwei Xia et al.
CELL DEATH & DISEASE (2018)
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study
Kakuhiro Yamaguchi et al.
IN VIVO (2018)
The ERK-ZEB1 pathway mediates epithelial mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids
L-Y Chiu et al.
ONCOGENE (2017)
Salinomycin acts through reducing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells
Chun-Liang Tung et al.
EXPERIMENTAL CELL RESEARCH (2017)
Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
Lijun Dong et al.
ONCOTARGET (2017)
Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/syndecan-1/TGF-β autocrine loop
Ye Zeng et al.
ONCOTARGET (2016)
Apatinib for molecular targeted therapy in tumor
Haijun Zhang
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17
Jing Ren et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2015)
Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor
Zhu Zeng et al.
LUNG CANCER (2014)
The Design of a Quantitative Western Blot Experiment
Sean C. Taylor et al.
BIOMED RESEARCH INTERNATIONAL (2014)
In vitro Cell Migration and Invasion Assays
Calvin R. Justus et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2014)
Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis
Yu Liu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
K. Takezawa et al.
BRITISH JOURNAL OF CANCER (2011)
Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: The association with treatment efficacy of pemetrexed
Chung-Yu Chen et al.
LUNG CANCER (2011)
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
Alex Chang
LUNG CANCER (2011)
ABCC11/MRP8 confers pemetrexed resistance in lung cancer
Takehiro Uemura et al.
CANCER SCIENCE (2010)
Significance of thymidylate synthase for resistance to pemetrexed in lung cancer
Hiroaki Ozasa et al.
CANCER SCIENCE (2010)
Genetic Determinants of Pemetrexed Responsiveness and Nonresponsiveness in Non-small Cell Lung Cancer Cells
Ming-Fang Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis
Daniel R. Budman et al.
ANTI-CANCER DRUGS (2006)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Future directions in the development of pemetrexed
H Calvert et al.
SEMINARS IN ONCOLOGY (2002)
Share Paper
